Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Barakat

Showing results (221-230 of 402) with videos related to

Pageof 41
Sort By:
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapyM Markman, B Reichman, T Hakes, et al.
Gynecologic Oncology|June 27, 2013
Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancerSarah A Milgrom, Marisa A Kollmeier, Nadeem R Abu-Rustum, et al.
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancerM Markman, T Hakes, B Reichman, et al.
Gynecologic Oncology|March 27, 2001
Risk of endometrial carcinoma associated with BRCA mutationD A Levine, O Lin, R R Barakat, et al.
Cancer|January 15, 1993
Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experienceM Markman, J L Lewis, P Saigo, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapyM Markman, L C DeMarco, M Birkhofer, et al.
Gynecologic Oncology|July 1, 1993
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group studyM Markman, E Rowinsky, T Hakes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancerM Markman, P Francis, E Rowinsky, et al.
Gynecologic Oncology|July 4, 2006
Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancerEric L Eisenhauer, Michael I D'Angelica, Nadeem R Abu-Rustum, et al.
Pageof 41

Showing results (221-230 of 402) with videos related to

Sort By:
Pageof 41
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Association between pretreatment CA-125 levels and surgically documented complete responses in patients with ovarian cancer treated with second-line intraperitoneal therapyM Markman, B Reichman, T Hakes, et al.
Gynecologic Oncology|June 27, 2013
Postoperative external beam radiation therapy and concurrent cisplatin followed by carboplatin/paclitaxel for stage III (FIGO 2009) endometrial cancerSarah A Milgrom, Marisa A Kollmeier, Nadeem R Abu-Rustum, et al.
Journal of Cancer Research and Clinical Oncology|January 11, 1992
Phase 2 trial of chronic low-dose oral etoposide as salvage therapy of platinum-refractory ovarian cancerM Markman, T Hakes, B Reichman, et al.
Gynecologic Oncology|March 27, 2001
Risk of endometrial carcinoma associated with BRCA mutationD A Levine, O Lin, R R Barakat, et al.
Cancer|January 15, 1993
Epithelial ovarian cancer in the elderly. The Memorial Sloan-Kettering Cancer Center experienceM Markman, J L Lewis, P Saigo, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1993
Phase II trial of zeniplatin (CL 286,558), a new patinum compound, in patients with advanced ovarian cancer previously treated with organoplatinum-based therapyM Markman, L C DeMarco, M Birkhofer, et al.
Gynecologic Oncology|July 1, 1993
Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancerM Markman, B Reichman, T Hakes, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 1992
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group studyM Markman, E Rowinsky, T Hakes, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1994
Intraperitoneal Taxol (paclitaxel) in the management of ovarian cancerM Markman, P Francis, E Rowinsky, et al.
Gynecologic Oncology|July 4, 2006
Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian cancerEric L Eisenhauer, Michael I D'Angelica, Nadeem R Abu-Rustum, et al.
Pageof 41